{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-098882","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2025-10-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.517395+00:00","generated_at":"2026-05-17T04:02:48.453414+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Theriva VIRAGE Phase 2b: VCN-01+GA OS 10.8mo (HR0.57, p=0.055), PFS 7.0mo (HR0.55, p=0.011)","bullets":["In FAS population, VCN-01 + GA improved median OS to 10.8 mo vs 8.6 mo (HR 0.57, p=0.055) and PFS to 7.0 vs 4.6 mo (HR 0.55, p=0.011).","Patients receiving 2 VCN-01 doses starting GA cycle 4 had OS 14.8 vs 11.6 mo (HR 0.44, p=0.046) and PFS 11.2 vs 7.4 mo (HR 0.48, p=0.017).","VCN-01 well tolerated; all 13 related serious adverse events resolved; common: flu-like symptoms (13.2%), transaminase increase (5.7%).","Data to be presented at ESMO 2025 mini oral session on Oct 20; abstract published. Study met primary endpoints."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-098882","json":"https://secwatch.observer/filing/0001104659-25-098882.json","markdown":"https://secwatch.observer/filing/0001104659-25-098882.md","text":"https://secwatch.observer/filing/0001104659-25-098882.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465925098882/0001104659-25-098882-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465925098882/tm2528558d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:02:48.453414+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}